CYTO - Altamira Therapeutics Ltd. Stock Price and Quote

CYTO [NASD]

Index	-	P/E	-	EPS (ttm)	-26.93	Insider Own	7.10%	Shs Outstand	1.17M	Perf Week	4.35%
Market Cap	3.45M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.09M	Perf Month	-45.97%
Income	-19.70M	PEG	-	EPS next Q	-	Inst Own	1.90%	Short Float / Ratio	1.73% / 0.43	Perf Quarter	-52.79%
Sales	1.40M	P/S	2.46	EPS this Y	3.70%	Inst Trans	45.40%	Short Interest	0.02M	Perf Half Y	-68.52%
Book/sh	10.85	P/B	0.27	EPS next Y	-	ROA	-87.70%	Target Price	-	Perf Year	-88.66%
Cash/sh	0.34	P/C	8.61	EPS next 5Y	-	ROE	-125.40%	52W Range	2.70 - 43.00	Perf YTD	-40.62%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-93.30%	Beta	1.45
Dividend %	-	Quick Ratio	0.20	Sales past 5Y	-	Gross Margin	-	52W Low	6.67%	ATR	0.40
Employees	17	Current Ratio	0.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	29.53	Volatility	5.95% 9.46%
Optionable	Yes	Debt/Eq	0.62	EPS Q/Q	18.70%	Profit Margin	-	Rel Volume	0.56	Prev Close	2.92
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 30 BMO	Payout	-	Avg Volume	43.26K	Price	2.88
Recom	-	SMA20	-29.28%	SMA50	-39.67%	SMA200	-66.45%	Volume	17,098	Change	-1.37%

Feb-07-23 08:47AM	Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023 ACCESSWIRE
Jan-27-23 08:47AM	Altamira Therapeutics Provides Business Update GlobeNewswire -12.89%
Jan-24-23 08:17AM	Altamira Therapeutics Provides Update on Clinical Trials with Bentrio GlobeNewswire -29.12%
Jan-10-23 08:47AM	Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th GlobeNewswire
Dec-19-22 08:47AM	Altamira Therapeutics Provides Year-End 2022 Business Update GlobeNewswire -14.16%
08:47AM	Loading…
Dec-02-22 08:47AM	Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia ACCESSWIRE
Nov-30-22 08:47AM	Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results GlobeNewswire -6.77%
08:07AM	Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma GlobeNewswire
Nov-22-22 08:47AM	In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability ACCESSWIRE +6.27%
Nov-10-22 08:47AM	Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event GlobeNewswire
Nov-09-22 08:47AM	Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement GlobeNewswire -9.52%
Nov-08-22 08:47AM	Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamiras Bentrio under Controlled Grass Pollen Exposure GlobeNewswire
Oct-24-22 08:47AM	Altamira Therapeutics Announces Reverse Stock Split GlobeNewswire -24.96%
Oct-21-22 08:47AM	Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets GlobeNewswire +58.64%
Oct-13-22 08:47AM	Altamira Therapeutics to Participate at RNA Leaders USA Congress GlobeNewswire
08:47AM	Loading…
Oct-03-22 08:47AM	Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia GlobeNewswire -7.42%
Sep-27-22 08:47AM	Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis GlobeNewswire +7.72%
Sep-13-22 08:47AM	Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19 GlobeNewswire
Sep-08-22 08:57AM	Altamira Therapeutics to Host Investor Call on September 14th GlobeNewswire -9.31%
07:17AM	Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit GlobeNewswire
Aug-30-22 09:24AM	Altamira Therapeutics Provides Business Update GlobeNewswire -5.94%
Aug-03-22 12:15PM	Altamira Therapeutics CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic Transformation GlobeNewswire
Aug-01-22 08:47AM	Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19 GlobeNewswire -5.55%
Jul-28-22 08:47AM	Altamira Therapeutics Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal GlobeNewswire +7.14%
Jul-25-22 08:47AM	Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint GlobeNewswire
Jul-19-22 08:47AM	Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy GlobeNewswire +17.11%
Jul-12-22 08:47AM	Altamira Therapeutics RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal ACCESSWIRE +11.32%
Jun-29-22 07:30AM	Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan ACCESSWIRE
Jun-27-22 08:30AM	Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis ACCESSWIRE +11.57%
Jun-23-22 08:47AM	Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19 ACCESSWIRE
08:47AM	Loading…
Jun-13-22 08:47AM	Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo ACCESSWIRE -5.85%
Jun-09-22 05:25PM	Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements ACCESSWIRE
Jun-08-22 08:47AM	Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray ACCESSWIRE
May-31-22 08:47AM	Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia ACCESSWIRE
May-23-22 08:47AM	Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray ACCESSWIRE
May-20-22 09:00AM	Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study ACCESSWIRE
May-19-22 09:00AM	Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference ACCESSWIRE +5.68%
May-18-22 08:47AM	Altamira Therapeutics Issues Shareholder Letter ACCESSWIRE
May-05-22 08:47AM	Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia ACCESSWIRE
Apr-19-22 09:00AM	Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19 ACCESSWIRE +6.37%
Apr-12-22 07:30AM	Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results ACCESSWIRE -31.33%
Apr-11-22 08:47AM	Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant ACCESSWIRE +55.14%
Apr-04-22 08:47AM	Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET ACCESSWIRE
Mar-15-22 09:00AM	Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio ACCESSWIRE
Mar-11-22 09:00AM	Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant ACCESSWIRE +36.70%
Mar-09-22 09:00AM	Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19 ACCESSWIRE
Mar-04-22 09:15AM	Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets ACCESSWIRE -10.99%
Feb-14-22 09:00AM	Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute Vertigo ACCESSWIRE
Feb-09-22 09:00AM	Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets ACCESSWIRE Test RSS
09:00AM	Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets ACCESSWIRE
Feb-07-22 09:00AM	Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries ACCESSWIRE
Feb-04-22 09:25AM	Altamira Therapeutics Establishes OTC Consumer Health Business Unit ACCESSWIRE +6.72%
Jan-21-22 09:00AM	Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia ACCESSWIRE -8.22%
Jan-13-22 09:00AM	Altamira Therapeutics Provides Update on RNA Therapeutics Program ACCESSWIRE -9.77%
Jan-05-22 09:00AM	Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference ACCESSWIRE -5.91%
Dec-29-21 09:15AM	Altamira Therapeutics Provides Update on Bentrio Program ACCESSWIRE +35.76%
Dec-16-21 09:00AM	Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite Allergy ACCESSWIRE
Dec-01-21 09:00AM	Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis ACCESSWIRE -7.91%
Nov-15-21 09:00AM	Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021 ACCESSWIRE
Nov-12-21 09:00AM	Altamira Therapeutics Reports Positive In vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta Variant ACCESSWIRE +53.29%
06:06AM	Altamira Therapeutics Stock Surges on Positive Covid-19 Nasal Spray Data Investing.com
Oct-25-21 09:00AM	Altamira Therapeutics and Wellesta Collaborate for Marketing and Distribution of Bentrio in Six Key Asian Markets ACCESSWIRE
Oct-14-21 08:00AM	Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application ACCESSWIRE +17.50%
Oct-06-21 08:00AM	Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference ACCESSWIRE -9.90%
Oct-01-21 08:04PM	Penny Stocks to Buy Using Technical Analysis for October 2021 Investopedia
Sep-27-21 07:45AM	Altamira Therapeutics Provides Update on Bentrio Program ACCESSWIRE
Sep-21-21 08:00AM	Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program ACCESSWIRE
Sep-09-21 08:30AM	Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference ACCESSWIRE
Sep-08-21 08:30AM	Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results ACCESSWIRE
Aug-06-21 09:00AM	Altamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1) ACCESSWIRE
Aug-03-21 09:00AM	Altamira Therapeutics Announces Launch of Website Dedicated to Bentrio(TM) Nasal Spray ACCESSWIRE

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience